Evaluation of urinary biomarkers of oxidative/nitrosative stress in adolescents and adults with Down syndrome

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 7, 2011, Pages 760-768

  Campos, Carlos ^a   Guzmán, Rodrigo ^a   López Fernández, Encarnación ^a   Casado, Ángela ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Biomarker; Down syndrome; Hypothyroidism; Nitrosative stress; Oxidative stress; Urine

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADVANCED GLYCATION END PRODUCT; HYDROGEN PEROXIDE; ISOPROSTANE; LEVOTHYROXINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; HUMAN; HYPOTHYROIDISM; MALE; NITROSATIVE STRESS; OXIDATIVE STRESS; PRIORITY JOURNAL; SPECTROPHOTOMETRY; URINALYSIS;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DEOXYGUANOSINE; DOWN SYNDROME; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPOTHYROIDISM; LIPID PEROXIDATION; MIDDLE AGED; NITROGEN COMPOUNDS; OXIDATIVE STRESS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; YOUNG ADULT;

EID: 79955598450     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.03.013     Document Type: Article

References (45)

1. Jovanovic S.V., Clements D., MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic. Biol. Med. 1998, 25:1044-1048.
2. Roizen N.J., Patterson D. Down's syndrome. Lancet 2003, 361:1281-1289.
3. Strydom A., Dickinson M.J., Shende S., Pratico D., Walker Z. Oxidative stress and cognitive ability in adults with Down syndrome. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:76-80.
4. Campos C., Guzmán R., López-Fernández E., Casado A. Urinary uric acid and antioxidant capacity in children and adults with Down syndrome. Clin. Biochem. 2010, 43:228-233.
5. Meguid N.A., Dardir A.A., El-Sayed E.M., Ahmed H.H., Hashish A.F., Ezzat A. Homocysteine and oxidative stress in Egyptian children with Down syndrome. Clin. Biochem. 2010, 43:963-967.
6. Morrow J.D., Roberts L.J. The isoprostanes: unique bioactive products of lipid peroxidation. Prog. Lipid Res. 1997, 36:1-21.
7. Bittles A.H., Bower C., Hussain R., Glasson E.J. The four ages of Down syndrome. Eur. J. Public Health 2007, 17:221-225.
8. Jaffé M. Über den niederschlag, welchen pikrinsäure in normalen harn erzeugt und über eine neue reaktion des kreatinins. Z. Physiol. Chem. 1886, 10:391-400.
9. Varley H., Gowenlock A.H., Bell M. Practical Clinical Biochemistry 1980, Heinemann Medical Books, London. 5th ed.
10. Uchiyama M., Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal. Biochem. 1978, 86:271-278.
11. Yanagisawa K., Makita Z., Shiroshita K., Ueda T., Fusegawa T., Kuwajima S., Takeuchi M., Koike T. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Metabolism 1998, 47:1348-1353.
12. Witko-Sarsat V., Friedlander M., Capeillere-Blandin C., Nguyen-Khoa T., Nguyen A.T., Zingraff J., Jungers P., Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996, 49:1304-1313.
13. Banerjee D., Kumar A.P., Kumar B., Madhusoodanan U.K., Nayak S., Jacob J. Determination of absolute hydrogen peroxide concentration by spectrophotometric method. Curr. Sci. 2002, 83:1193-1194.
14. Miranda K.M., Espey M.G., Wink D.A. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001, 5:62-71.
15. Pallardó F.V., Degan P., d'Ischia M., Kelly F.J., Zatterale A., Calzone R. Multiple evidence for an early age pro-oxidant state in Down syndrome patients. Biogerontology 2006, 7:211-220.
16. Seidl R., Greber S., Schuller E., Bernert G., Cairns N., Lubec G. Evidence against increased oxidative DNA-damage in Down syndrome. Neurosci. Lett. 1997, 235:137-140.
17. Honda M., Yamada Y., Tomonaga M., Ichinose H., Kamihira S. Correlation of urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG), a biomarker of oxidative DNA damage, and clinical features of hematological disorders: a pilot study. Leuk. Res. 2000, 24:461-468.
18. Song M.-F., Li Y.-S., Ootsuyama Y., Kasai H., Kawai K., Ohta M., Eguchi Y., Yamato H., Matsumoto Y., Yoshida R., Ogawa Y. Urea, the most abundant component in urine, cross-reacts with a commercial 8-OH-dG ELISA kit and contributes to overestimation of urinary 8-OH-dG. Free Radic. Biol. Med. 2009, 47:41-46.
19. Pueschel S.M., Craig W.Y., Haddow J.E. Lipids and lipoproteins in persons with Down's syndrome. J. Intellect. Disabil. Res. 1992, 36:365-369.
20. Murphy E.J., Schapiro M.B., Rapoport S.I., Shetty H.U. Phospholipid composition and levels are altered in Down syndrome brain. Brain Res. 2000, 867:9-18.
21. Oppermann U. Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu. Rev. Pharmacol. Toxicol. 2007, 47:293-322.
22. Balcz B., Kirchner L., Cairns N., Fountoulakis M., Lubec G. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J. Neural Transm. Suppl. 2001, 61:193-201.
23. Nagyova A., Sustrova M., Raslova K. Serum lipid resistance to oxidation and uric acid levels in subjects with Down's syndrome. Physiol. Res. 2000, 49:227-231.
24. Nyyssonen K., Porkkala-Sarataho E., Kaikkonen J., Salonen J.T. Ascorbate and urate are the strongest determinants of plasma antioxidative capacity and serum lipid resistance to oxidation in Finnish men. Atherosclerosis 1997, 130:223-233.
25. Tiano L., Padella L., Carnevali P., Gabrielli O., Bruge F., Principi F., Littarru G.P. Coenzyme Q10 and oxidative imbalance in Down syndrome: biochemical and clinical aspects. Biofactors 2008, 32:161-167.
26. Song X., Bao M., Li D., Li Y.M. Advanced glycation in d-galactose induced mouse aging model. Mech. Ageing Dev. 1999, 108:239-251.
27. Bernheim J., Rashid G., Gavrieli R., Korzets Z., Wolach B. In vitro effect of advanced glycation end-products on human polymorphonuclear superoxide production. Eur J Clin Invest 2001, 31:1064-1069.
28. DiMarco T., Giulivi C. Current analytical methods for the detection of dityrosine, a biomarker of oxidative stress, in biological samples. Mass Spectrom. Rev. 2007, 26:108-120.
29. Hensley K., Maidt M.L., Yu Z., Sang H., Markesbery W.R., Floyd R.A. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J. Neurosci. 1998, 18:8126-8132.
30. Giulivi C., Traaseth N.J., Davies K.J.A. Tyrosine oxidation products: analysis and biological relevance. Amino Acids 2003, 25:227-232.
31. Yuen J.W., Benzie I.F. Hydrogen peroxide in urine as a potential biomarker of whole body oxidative stress. Free Radic. Res. 2003, 37:1209-1213.
32. Halliwell B., Long L.H., Yee T.P., Lim S., Kelly R. Establishing biomarkers of oxidative stress: the measurement of hydrogen peroxide in human urine. Curr. Med. Chem. 2004, 11:1085-1092.
33. Banerjee D., Madhusoodanan U.K., Nayak S., Jacob J. Urinary hydrogen peroxide: a probable marker of oxidative stress in malignancy. Clin. Chim. Acta 2003, 334:205-209.
34. Mizutani T., Layon A.J. Clinical applications of nitric oxide. Chest 1996, 110:506-524.
35. Sohn Y.K., Ganju N., Bloch K.D., Wands J.R., de la Monte S.M. Neuritic sprouting with aberrant expression of the nitric oxide synthase III gene in neurodegenerative diseases. J. Neurol. Sci. 1999, 162:133-151.
36. Elli M., Soylemezoglu O., Erbas D., Bakkaloglu S.A., Buyan N., Ozkaya O., Hasanoglu E. Plasma and urine nitric oxide levels in healthy Turkish children. Pediatr. Nephrol. 2005, 20:1605-1609.
37. Murdoch J.C., Ratcliffe W.A., McLarty D.G., Rodger J.C., Ratcliffe J.G. Thyroid function in adults with Down's syndrome. J. Clin. Endocrinol. Metab. 1977, 44:453-458.
38. Sarandöl E., Taş S., Dirican M., Serdar Z. Oxidative stress and serum paraoxonase activity in experimental hypothyroidism: effect of vitamin E supplementation. Cell Biochem. Funct. 2005, 23:1-8.
39. Montenegro J., González O., Saracho R., Aguirre R., González O., Martínez I. Changes in renal function in primary hypothyroidism. Am. J. Kidney Dis. 1996, 27:195-198.
40. Prasher V., Haque M.S. Misdiagnosis of thyroid disorders in Down syndrome: time to re-examine the myth?. Am. J. Ment. Retard. 2005, 110:23-27.
41. Nève J., Sinet P.M., Molle L., Nicole A. Selenium, zinc and copper in Down's syndrome (trisomy 21): blood levels and relations with glutathione peroxidase and superoxide dismutase. Clin. Chim. Acta 1983, 133:209-214.
42. Shaposhnikov A.M., Khal'chitskii S.E., Shvarts E.I. Disorders of phenylalanine and tyrosine metabolism in Down's syndrome. Vopr. Med. Khim. 1979, 25:15-19.
43. Dowjat W.K., Adayev T., Kuchna I., Nowicki K., Palminiello S., Hwang Y.W., Wegiel J. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci. Lett. 2007, 413:77-81.
44. Coburn S.P., Seidenberg M., Mertz E.T. Clearance of uric acid, urea, and creatinine in Down's syndrome. J. Appl. Physiol. 1967, 23:579-580.
45. Lo A., Brown H.G., Fivush B.A., Neu A.M., Racusen L.C. Renal disease in Down syndrome: autopsy study with emphasis on glomerular lesions. Am. J. Kidney Dis. 1998, 31:329-335.